Combination chemotherapy and immunotherapy for resectable bile duct cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding an immunotherapy drug (rilvegostomig) to standard chemotherapy before surgery can improve outcomes for patients with early-stage bile duct cancer that can be completely removed. The treatment aims to shrink the tumor and help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of bile duct cancer called intrahepatic cholangiocarcinoma that your doctor believes can be fully removed with surgery.
- You haven't had chemotherapy, targeted therapy, or immunotherapy for this cancer before.
- You are generally in good health (able to carry out daily activities) and your life expectancy is more than 3 months.
- Your cancer has not spread to other parts of the body (no distant metastases) and hasn't invaded nearby organs that would make surgery impossible.
- You have adequate organ function, including blood counts, liver and kidney tests, and can provide a tumor sample for testing.
- You are willing to follow the study plan and use effective contraception if you are of childbearing potential.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination—cisplatin, gemcitabine (standard chemotherapy), and rilvegostomig (an immunotherapy)—given before and after surgery for a specific type of liver cancer called intrahepatic cholangiocarcinoma. The goal is to reduce the chance of the cancer coming back after surgery.
This trial tests a combination of three drugs for bile duct cancer that cannot be removed by surgery: sintilimab (an immunotherapy that helps your immune system fight cancer), bevacizumab (a drug that blocks blood vessel growth to tumors), and a standard chemotherapy called AG (gemcitabine and capecitabine). The goal is to see if this combination can help shrink or control the cancer as a first treatment option.
This trial tests a combination of an immunotherapy (adebrelimab), a targeted therapy (apatinib), and two chemotherapy drugs (gemcitabine and cisplatin) given before surgery for biliary tract cancers that are removable but at high risk of coming back. The goal is to see if this approach helps shrink the tumor and improve outcomes after surgery.
This trial tests a new combination of immunotherapy (tislelizumab), radiation, and chemotherapy before surgery for people with bile duct cancer that is hard to remove. The goal is to shrink the tumor enough to allow successful surgery.
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
This study tests a combination of three drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy (tislelizumab) for people with advanced biliary tract cancer who haven't had treatment yet. The goal is to see if this cocktail shrinks tumors better than standard care.
Hear when a new Cholangiocarcinoma Resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.